Trial · NCT00923247
Results by group53
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 53
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase I: Maximum Tolerated Dose (MTD) of Daily Oral Vandetanib | Phase 1 | 300 | mg | ||
| Phase I: Maximum Tolerated Dose (MTD) of Daily Oral Bortezomib | Phase 1 | 1.3 | mg/m^2 | ||
| Phase 2: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Phase 2 A | Complete Response | 0 | Participants | |
| Phase 2: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Phase 2 A | Partial Response | 0 | Participants | |
| Phase 2: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Phase 2 A | Stable Disease | 0 | Participants | |
| Phase 2: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Phase 2 A | Progressive Disease | 1 | Participants | |
| Phase 2: Progression Free Survival in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib | Phase 2 A - Vandetanib and Bortezomib at the MTD | 3.67 | months | ||
Response Rate (Complete Response (CR) + Partial Response (PR) of Adults With a Diagnosis of MTC Treated With Either of Two Regimens: (1) Daily Oral Vandetanib and Bortezomib or (2) Daily Oral Vandetanib | Phase 1 | Complete Response | 0 | Participants | |
Response Rate (Complete Response (CR) + Partial Response (PR) of Adults With a Diagnosis of MTC Treated With Either of Two Regimens: (1) Daily Oral Vandetanib and Bortezomib or (2) Daily Oral Vandetanib | Phase 2A | Complete Response | 0 | Participants | |
Response Rate (Complete Response (CR) + Partial Response (PR) of Adults With a Diagnosis of MTC Treated With Either of Two Regimens: (1) Daily Oral Vandetanib and Bortezomib or (2) Daily Oral Vandetanib | Phase 1 | Partial Response | 6 | Participants | |
Response Rate (Complete Response (CR) + Partial Response (PR) of Adults With a Diagnosis of MTC Treated With Either of Two Regimens: (1) Daily Oral Vandetanib and Bortezomib or (2) Daily Oral Vandetanib | Phase 2A | Partial Response | 0 | Participants | |
| Progression Free Survival (PFS) | Phase 1 | 30.2 | Full Range 1.8 to 93.67 | Months | |
| Progression Free Survival (PFS) | Phase 2A | 3.02 | Months | ||
| Number of Participants With Adverse Events | Phase 1 | 21 | Participants | ||
| Number of Participants With Adverse Events | Phase 2 A | 0 | Participants | ||
| Number of Participants With Tumor Biomarker Calcitonin (CTN) Response | Phase 1 | Complete response | 0 | Participants | |
| Number of Participants With Tumor Biomarker Calcitonin (CTN) Response | Phase 2A | Complete response | 0 | Participants | |
| Number of Participants With Tumor Biomarker Calcitonin (CTN) Response | Phase 1 | Partial response | 5 | Participants | |
| Number of Participants With Tumor Biomarker Calcitonin (CTN) Response | Phase 2A | Partial response | 0 | Participants | |
| Number of Participants With Tumor Biomarker Calcitonin (CTN) Response | Phase 1 | Stable disease | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00923247/results